• Users Online: 50
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2021  |  Volume : 54  |  Issue : 1  |  Page : 7-10

Postablation and α-1 blocker therapy in children with congenital obstructing posterior urethral membrane


1 Department of Pediatric Surgery AIIMS, New Delhi, India
2 Department of Trauma, Apex Trauma Centre Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

Correspondence Address:
Amit Kumar Singh
Department of Trauma Surgery, Apex Trauma Centre, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow - 226 014, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/fjs.fjs_97_20

Rights and Permissions

Background: Congenital obstructing posterior urethral membrane (COPUM) or posterior urethral valve (PUV) is the most common cause of lower urinary tract obstruction in boys. Approximately one-third of boys with PUV develop end-stage renal disease. Various prognostic factors have been recognized which determines the long-term outcome of these cases. Materials and Methods: This was a retrospective case–control analysis of data from January 1998 to May 2014. All patients of COPUM with radiological evidence of bladder neck hypertrophy with follow-up of 7 years were included in the study. Patients with urethral strictures, neurogenic bladder, and incomplete records were excluded. Group I (n = 57) received selective α-1 blocker (prazosin), after valve ablation. Group II (n = 36) who had not received the α-1 blocker was treated as a control group. Investigations include renal function test, ultrasonography, micturating cystourethrography renal dynamic scan, and glomerular filtration rate. Statistical analysis was done using the paired t-test, multiple serial analyses using ANOVA. P <0.05 was considered as significant. Results: A total of 113 patients of COPUM were treated from January 1998 to May 2014. Out of these 113, 93 patients (82.3%) were included in the study. Fifty-seven (61.2%) received α-1 blocker, while 36 patients (38.8%) acted as control. Significant decrease in bladder neck hypertrophy noted in Group I as compared to Group II (P<0.001). Conclusion: Uses of alpha-1 blocker hastens the recovery in terms of clinical improvement, resolution of bladder neck hypertrophy, and improved peak urine flow rate.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed483    
    Printed0    
    Emailed0    
    PDF Downloaded62    
    Comments [Add]    

Recommend this journal